The Logic of Medical Co-Payments

Aaron Carroll had a very useful NYT Upshot piece highlighting research showing that even modest co-payments discourage people from getting necessary medical care. The article is about co-payments for prescription drugs where it highlights research showing that people will often skip taking prescribed drugs to avoid co-payments. There are a couple of points worth making about co-payments in this context and more generally.

First, if a drug has been prescribed for a patient, then it is the judgement of a medical professional that they need this drug for their health. The argument for co-pays, that we want people to think twice before getting the treatment, really should not apply here since a medical professional has determined that they do need the treatment. It doesn’t make sense in general to encourage people to substitute their own judgement for that of a medical professional. (That doesn’t mean that medical professionals will always be right, but it would be best if patients made the determination to ignore their judgement based on their own research, not the desire to save a co-pay.)

The other point is that drugs are almost invariably cheap. By this I mean that they are cheap to manufacture and distribute. The research can be expensive, but this is a sunk cost at the point where the drug is being prescribed for the patient. If all drugs sold as generics, with no patent or related protections, they would rarely cost more than $10 or $20 per prescription. For this reason, there is not much savings to society if we get people to take fewer drugs, we are just risking people’s health with co-pays.

We do need to pay for the research. I suggest doing this upfront, with the government contracting out to private firms. All results and patents are in the public domain. (See Rigged, chapter 5 [it’s free].)

The issue with drugs is qualitatively different than with doctors’ visits. First, a visit to the doctor does require the use of a doctor’s time, as well as the time of their support staff and possibly other health care professionals. This means that there actually are savings from discouraging unnecessary visits.

The second point is that a decision to visit a doctor depends on the patient’s judgement, not that of a medical professional. (This is not the case with repeat treatments, just an initial visit.) People will always weigh a number of factors in deciding whether to visit a doctor, whether or not there is a co-pay.

For example, if they have a busy schedule or long-planned travel, they may choose not to see a doctor for a particular issue where they might otherwise see a doctor. In this context, it may be very reasonable to have a modest co-payment (e.g. $20 per visit — which would be waved for low income people) to make people think twice before seeing a doctor.

This sort of co-payment can be seen as analogous to charging people five cents for using a plastic bag when they shop, as many cities now do. If someone really wants the bag, the five cent fee will not prevent them from getting it, but it does get people to think twice, and therefore has led to a large decline in usage.

It is reasonable to think that a modest co-pay could have a similar effect on doctors visits. It should not prevent people with serious health issues from seeing a doctor, but it may discourage some visits for relatively trivial matters, like a cold.

Note, this is not the “skin in the game” story pushed by many economists, which wants patients to be comparative shoppers. There is considerable evidence that patients generally are not good at weighing the relative price of different treatments, and when they do, they often make the wrong choice for their health.

This is simply arguing that it would be good if patients think twice before rushing to see a doctor. We can’t guarantee that this will never mean that a person who needed to see a doctor chose not to, but in the alternative, we can’t guarantee that a person in desperate need to see a doctor won’t have to wait because the person in front of them in line has a cold.

This article first appeared on Dean Baker’s Beat the Press blog.

More articles by:

Dean Baker is the senior economist at the Center for Economic and Policy Research in Washington, DC. 

December 11, 2019
Vijay Prashad
Why the Afghanistan Papers Are an Eerie Reminder of Vietnam
Kenneth Surin
Australia’s Big Smoke
Sameer Dossani
Ideology or Popularity: How Will Britain Vote?
John W. Whitehead
Who Will Protect Us From an Unpatriotic Patriot Act?
Binoy Kampmark
Interference Paranoia: Russia, Reddit and the British Election
Scott Tucker
Sure, Impeach Trump, But Let’s be Honest
Nyla Ali Khan
Homogenizing India: the Citizenship Debate
Thomas Knapp
Congress: The Snail’s Pace Race
Shawn Fremstad
Modern Family Progressivism
Joseph Essertier
Julian Assange, Thanks for Warning Japanese About Washington
William Minter
How Africa Could Power a Green Revolution
December 10, 2019
Tony McKenna
The Demonization of Jeremy Corbyn
John Grant
American Culture Loves a Good Killer
Jacob Hornberger
Afghanistan: a Pentagon Paradise Built on Lies
Nick Licata
Was Trump Looking for Corruption or a Personal Favor?
Thomas M. Magstadt
What’s the Matter With America?
Brian Tokar
Climate Talks in Madrid: What Will It Take to Prevent Climate Collapse?
Ron Jacobs
Where Justice is a Game: Impeachment Hearings Redux
Jack Rasmus
Trump vs. Democracy
Walden Bello
Capitalism with Chinese Characteristics
Binoy Kampmark
A Troubled Family: NATO Turns 70
Brian Horejsi
Citizens Are Never Trusted
Michael Barker
Self-Defense in the Civil Rights Movement: the Lessons of Birmingham, 1963
John Feffer
Soldiers Who Fight War
Howie Wolke
Willingness to Compromise Puts Wilderness at Risk
December 09, 2019
Jefferson Morley
Trump’s Hand-Picked Prosecutor John Durham Cleared the CIA Once, Will He Again?
Kirkpatrick Sale
Political Collapse: The Center Cannot Hold
Ishmael Reed
Bloomberg Condoned Sexual Assault by NYPD 
W. T. Whitney
Hitting at Cuban Doctors and at Human Solidarity
Louisa Willcox
The Grizzly Cost of Coexistence
Thomas Knapp
Meet Virgil Griffith: America’s Newest Political Prisoner
John Feffer
How the New Right Went Global — and How to Stop It
Ralph Nader
Why Not Also Go With “The Kitchen Table” Impeachable Offenses for Removal?
Robert Fisk
Meet the Controversial Actor and Businessman Standing Up Against Egypt’s el-Sisi
M. K. Bhadrakumar
Sri Lanka Continues Its Delicate Dance With India
Dahr Jamail
Savoring What Remains: Dealing With Climate PTSD
George Wuerthner
Bison Slaughter in Yellowstone…Again
Scott Tucker
Premature Democratic Socialists: Reasons for Hope and Change
Julian Rose
Polish Minister of Health Proposes Carcinogenic 5G Emission Levels as National Norm
Dean Baker
Coal and the Regions Left Behind
Robert Koehler
Envisioning a United World
Weekend Edition
December 06, 2019
Friday - Sunday
Jeffrey St. Clair
Eat an Impeachment
Matthew Hoh
Authorizations for Madness; The Effects and Consequences of Congress’ Endless Permissions for War
Jefferson Morley
Why the Douma Chemical Attack Wasn’t a ‘Managed Massacre’
Andrew Levine
Whatever Happened to the Obama Coalition?